Phase 3 Readout
JAZZ: Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezoliz
August 13, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 13, 2026
- Company
- Jazz Pharmaceuticals plc (JAZZ)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezoliz
- Indication
- Small-Cell Lung Cancer